Early Trial: Personalised Vaccine for Ovarian Cancer Proves FeasibleBy Ava ThompsonOctober 16, 2026 A phase 1 trial reports a personalised NeoVax vaccine with nivolumab was feasible in platinum-sensitive ovarian cancer, with an acceptable safety profile.
